The Annals the journal of Pharmacy Technology
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


The Annals of Pharmacotherapy: Vol. 35, No. 2, pp. 242-248. DOI 10.1345/aph.10043
© 2001 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Struckman, D.
Right arrow Articles by Rivey, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Struckman, D.
Right arrow Articles by Rivey, M.


Research Articles

Combined therapy with an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor in heart failure

DR Struckman and MP Rivey

OBJECTIVE: To evaluate the safety, tolerability, and efficacy of chronic combination therapy with an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin II receptor blocker (ARB) in the management of heart failure. DATA SOURCES: Clinical literature was accessed through MEDLINE (January 1966-June 2000). Key search terms included angiotensin-converting enzyme inhibitor; losartan; combined modality therapy; drug effects; heart failure, congestive; and receptors, angiotensin. DATA SYNTHESIS: Heart failure is widely prevalent and continues to be associated with high morbidity and mortality, even with currently recommended care. At the moderate doses studied for patients with mild heart failure in brief trials, combined ACE inhibitor and ARB therapy was well tolerated and had an additive effect in reducing blood pressure and relieving symptoms of heart failure. CONCLUSIONS: An ARB combined with an ACE inhibitor may benefit heart failure patients who are receiving all other recommended therapies. Further trials are needed to evaluate long-term safety effectiveness, quality of life, and survival before the combination can be recommended for routine use.


This article has been cited by other articles:


Home page
Arch Intern MedHome page
C. O. Phillips, A. Kashani, D. K. Ko, G. Francis, and H. M. Krumholz
Adverse Effects of Combination Angiotensin II Receptor Blockers Plus Angiotensin-Converting Enzyme Inhibitors for Left Ventricular Dysfunction: A Quantitative Review of Data From Randomized Clinical Trials
Arch Intern Med, October 8, 2007; 167(18): 1930 - 1936.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
D. A Sica
Review: The practical aspects of combination therapy with angiotensin receptor blockers and angiotensin-converting enzyme inhibitors
Journal of Renin-Angiotensin-Aldosterone System, June 1, 2002; 3(2): 66 - 71.
[Abstract] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 2001 by Harvey Whitney Books Company.